Cancer discovery
-
England's Cancer Drugs Fund will reduce the number of indications it pays for by nearly 30%. Projections suggested that the cost of the fund would have more than doubled by the end of the year, and the cuts will save £80 million ($121 million) by eliminating drugs such as eribulin and ziv-aflibercept.
-
In a phase II trial, the tyrosine kinase inhibitor sunitinib was effective in previously treated patients with thymic carcinoma, offering the first viable second-line treatment option for patients with this rare and aggressive form of thymus cancer.